Search alternatives:
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
ms decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
10 mg » 100 mg (Expand Search), 50 mg (Expand Search)
_ we » _ web (Expand Search), _ wet (Expand Search), _ e (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
ms decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
10 mg » 100 mg (Expand Search), 50 mg (Expand Search)
_ we » _ web (Expand Search), _ wet (Expand Search), _ e (Expand Search)
-
1
Trial profile.
Published 2024“…The open-label WHICH clinical trial, conducted at two sites in South Africa from 2018–2019, randomized HIV-negative women aged 18–40 years to 150 mg DMPA-IM 12-weekly (n = 262) or 200 mg NET-EN 8-weekly (n = 259). We measured testosterone by UHPLC-MS/MS and SHBG by immunoassay in matched pairs of serum samples collected at baseline (D0) and at peak serum progestin levels at 25 weeks post initiation (25W) (n = 214–218 pairs). …”
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
Weighted odds ratios reflecting the impact of a genetically determined 10 mg/dL decrease in LDL-C on safety and efficacy endpoints.
Published 2020“…<p>Odds ratio and 95% confidence interval is displayed for the effect of a genetically determined 10 mg/dL decrease in LDL-C on safety and efficacy endpoints for White individuals, Black individuals, Hispanic individuals, and inverse variance weighted meta-analysis of White, Black, and Hispanic populations (IVWMA). …”
-
17
-
18
-
19
Baseline patient characteristics.
Published 2025“…However, the effects of these agents on respiratory variability, which reflects the adaptability of the respiratory system, have not been thoroughly explored. We evaluated these effects in a randomized controlled pilot trial. …”
-
20